Actavis to Re-launch Generic Pulmicort RESPULES® Following Favorable Appeals Court Ruling
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Guggenheim Raises PT After Actavis (ACT) Has 1Q15 EPS Beat
May 11, 2015 10:57 AM EDTGuggenheim reiterates their Buy rating on Actavis (NYSE: ACT), and raised the price target to $355.00 (from $345.00), following a 1Q15 beat. ACT reported an adjusted 1Q15 diluted EPS of $4.30. This came $0.34 higher than consensus, and $0.41 better than Guggenheim estimates.
Guggenheim analyst, Louise Chen,... More
